XyloCor

Gene therapy developer XyloCor adds $22.6M to expand clinical trial plans

With the extension to its Series A financing, XyloCor plans a clinical trial testing its gene therapy as an adjunct to coronary artery bypass graft surgery. A study in refractory angina is already underway.

By Frank Vinluan

BioPharma, Startups

XyloCor closes $17M Series A round to develop gene therapy for refractory angina

The Philadelphia-based company has an IND open with the FDA and plans to begin its clinical trial in the first half of next year.

By Alaric DeArment

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.